A dual-reporter correction to enhance the performance of electrochemical aptamer-based sensors in whole blood.
Historically, several methods have been employed to quantify small molecules and biomarkers in diluted or undiluted blood. However, these methods are very cumbersome and some of them only work for diluted whole blood. Further, they usually fail when applied for real-time, continuous monitoring of the target of interests in whole blood. While such a technology could, for example, provide maximal information about drug levels in blood throughout the day and enable sensitive, real-time dose adjustments and optimal treatment decisions for the patients, achieving this has proven difficult as the design and preparation molecular sensors that can be used in whole blood for real-time and long-term measurements has proven very challenging.
To combat this, researchers at UC Santa Barbara have created a dual-reporter correction to enhance the performance of electrochemical aptamer-based sensors in whole blood. This sensor architecture paves a way to real-time and continuous metabolic, pharmacokinetic and drug-response measurements. The approach largely eliminates the drift observed for both cocaine and aminoglycoside-detecting E-AB sensors, reducing drift of order 25% - 30% to less than 2% over many hours of continuous operation in flowing, undiluted whole blood.
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 11,202,587 | 12/21/2021 | 2016-99M |
indpharma, Sensors, Electrochemical aptamer-based sensors